EBV REACTIVATION AND PTLD IN THE LETERMOVIR ERA: BEYOND ANTIVIRAL PROPHYLAXIS (EBMT 2026) - Mar 14, 2026 - Abstract #B086; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "IIn this real-world allo-HSCT cohort, EBV-R and PTLD increased over time and were associated with ATG, PTCy, and donor type. Day-30 immune reconstitution was a key risk factor. EBV-R/PTLD were marked by poor T-cell recovery, increased NK- and B-cells, and a protective effect from higher early CD4⁺ and activated NK/T-cells."
Aplastic Anemia • Bone Marrow Transplantation • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • CD4 • CD8
|
|
Ilaria Cutini1; Chiara Camerini1; Giacomo Coltro1; Antonella Gozzini1; Edoardo Simonetti1; Mirella Giordano1; Gaia Mirabella1; Alessio Mazzoni1; Francesca Matani1; Francesco Annunziato1; Alessandro Maria Vannucchi1; Chiara Nozzoli1
|